Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 3

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 38Head & Neck 7Genitourinary 5Sarcoma 3CNS 3Breast 3Gastrointestinal 2Dermatologic 2Gynecologic 1Endocrine 1

Conditions

Breast Neoplasms 3Lung Neoplasms 1Breast Neoplasms, Male 1

Interventions

Trastuzumab 260Paclitaxel 216Cyclophosphamide 173Docetaxel 146Letrozole 126Fulvestrant 121Capecitabine 121Doxorubicin 111Carboplatin 98Bevacizumab 90exemestane 88Anastrozole 85Tamoxifen 77Lapatinib 77pembrolizumab 68Albumin-Bound Paclitaxel 67pertuzumab 62palbociclib 60Taxes 59Gemcitabine 57eribulin 48130-nm albumin-bound paclitaxel 47Radiotherapy 46Everolimus 44Ado-Trastuzumab Emtansine 43Vinorelbine 39ixabepilone 32Epirubicin 30Cisplatin 30pegfilgrastim 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Gefitinib × Breast × Clear all
NCT00086957 2017-02-27

Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer

City of Hope Medical Center

Phase 1/2 Completed
31 enrolled 10 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00357734 2016-08-30

Iressa Follow-up Trial

AstraZeneca

Phase 3 Completed
14 enrolled 10 charts
BreastThoracic

Breast Neoplasms, Lung Neoplasms

NCT00057941 2014-05-12

Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer

National Cancer Institute (NCI)

Phase 2 Completed
148 enrolled 7 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡